Nxera pharma notes successful development progress of partnered schizophrenia candidate nbi-1117568

Tokyo, japan and cambridge, uk, 16 april 2024 – nxera pharma co., ltd. (“nxera” or “the company; tse 4565) – formerly known as sosei group or sosei heptares – has been notified by its partner neurocrine biosciences inc. (“neurocrine”; nasdaq: nbix) that nbi-1117568, an oral selective muscarinic m4 receptor agonist being advanced in phase 2 clinical trials by neurocrine for the treatment of schizophrenia and other neuropsychiatric disorders, has successfully completed a long-term preclinical toxicity program that meets us fda requirements to allow for safe, chronic (i.e. long-term) dosing in future clinical trials. the achievement of this important safety development milestone triggers a $15 million payment to nxera from neurocrine.
NBIX Ratings Summary
NBIX Quant Ranking